Monte Rosa Therapeutics reported that MRT-8102 effectively normalized key pathogenic factors of atherosclerotic cardiovascular disease in obese patients at high cardiovascular risk during the GFORCE-1 Phase 1 study.

Observed price moves

• GLUE-6.84%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.